- Home
- PHAR vs MLYS Comparison
PHAR vs MLYS Comparison
Compare PHAR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- MLYS
- Stock Information
- Founded
- PHAR 1988
- MLYS 2019
- Country
- PHAR Netherlands
- MLYS United States
- Employees
- PHAR N/A
- MLYS N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- MLYS Health Care
- Exchange
- PHAR Nasdaq
- MLYS Nasdaq
- Market Cap
- PHAR 679.0M
- MLYS 634.6M
- IPO Year
- PHAR N/A
- MLYS 2023
- Fundamental
- Price
- PHAR $9.09
- MLYS $10.52
- Analyst Decision
- PHAR Strong Buy
- MLYS Strong Buy
- Analyst Count
- PHAR 3
- MLYS 2
- Target Price
- PHAR $27.00
- MLYS $30.00
- AVG Volume (30 Days)
- PHAR 6.6K
- MLYS 273.6K
- Earning Date
- PHAR 03-13-2025
- MLYS 11-11-2024
- Dividend Yield
- PHAR N/A
- MLYS N/A
- EPS Growth
- PHAR N/A
- MLYS N/A
- EPS
- PHAR N/A
- MLYS N/A
- Revenue
- PHAR $285,745,000.00
- MLYS N/A
- Revenue This Year
- PHAR $20.08
- MLYS N/A
- Revenue Next Year
- PHAR $9.22
- MLYS N/A
- P/E Ratio
- PHAR N/A
- MLYS N/A
- Revenue Growth
- PHAR 30.64
- MLYS N/A
- 52 Week Low
- PHAR $6.65
- MLYS $8.58
- 52 Week High
- PHAR $13.20
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- PHAR 46.17
- MLYS 43.56
- Support Level
- PHAR $9.37
- MLYS $9.18
- Resistance Level
- PHAR $10.01
- MLYS $9.97
- Average True Range (ATR)
- PHAR 0.50
- MLYS 0.85
- MACD
- PHAR -0.13
- MLYS -0.08
- Stochastic Oscillator
- PHAR 0.00
- MLYS 38.05
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.